Round Rock Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Round Rock
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Round Rock News
Whizzo raises M in Series A round led by Fundamentum to deepen R&D
Whizzo will use the capital to expand its science and engineering teams, invest in fundamental research, and deepen its manufacturing partnerships as it scales its technical textiles platform globally ...
Materials science startup Whizzo raises million in Series A led by Fundamentum
Funds to drive materials science research, build in-house IP, and double export markets to more than over 30 countries ...
Nandan Nilekani’s Fundamentum leads million bet on materials science startup Whizzo
Whizzo has raised million in a round led by Nandan Nilekani’s Fundamentum, with participation from South Korea-based deeptech player LB Investment, and existing backers Lightspeed Venture Partners ...
JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabilis, Enodia Emerges & More
Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year.